Pertinence des prescriptions d’anticoagulants oraux à la sortie d’un service de médecine interne d’un hôpital régional suisse

Gouin-Thibault, 2011, Nouveaux anticoagulants par voie orale : quelle place pour les analyses de biologie médicale ?, Sang Thromb Vaiss, 23, 8 Gschwind, 2013, Identification and weighting of the most critical “real-life” drug-drug interactions with acenocoumarol in a tertiary care hospital, Eur J Clin Pharmacol, 69, 617, 10.1007/s00228-012-1358-7 Galanaud, 2015, [Management of venous thromboembolism: A 2015 update], Rev Med Interne, 36, 746, 10.1016/j.revmed.2015.06.004 Haschke, 2012, Clinical pharmacological aspects of new oral anticoagulants, Ther Umsch, 69, 657, 10.1024/0040-5930/a000344 Kazmi, 2011, New anticoagulants: how to deal with treatment failure and bleeding complications, Br J Clin Pharmacol, 72, 593, 10.1111/j.1365-2125.2011.04060.x Vogel, 2015, [Anticoagulation in atrial fibrillation in the elderly: the geriatrician point of view with a focus on the direct oral anticoagulants], Rev Med Interne, 36, 22, 10.1016/j.revmed.2014.08.005 Albers, 1996, Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals, Arch Intern Med, 156, 2311, 10.1001/archinte.1996.00440190053006 Ang, 1998, Review of antithrombotic drug usage in atrial fibrillation, J Clin Pharm Ther, 23, 97, 10.1046/j.1365-2710.1998.00148.x Bo, 2003, Warfarin for non-valvar atrial fibrillation: still underused in the 21st century?, Heart, 89, 553, 10.1136/heart.89.5.553 Bo, 2007, Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study, BMC Public Health, 7, 203, 10.1186/1471-2458-7-203 Mortimer, 2005, Automatic drug use audit in primary care – a pilot evaluation of warfarin use for patients with atrial fibrillation, Aust Fam Physician, 34, 798 Nilsson, 2004, Anticoagulant treatment of patients with chronic atrial fibrillation in primary health care in Sweden – a retrospective study of incidence and quality in a registered population, Fam Pract, 21, 612, 10.1093/fampra/cmh606 Singh, 2011, Evaluation of antithrombotic usage for atrial fibrillation in aged care facilities, J Clin Pharm Ther, 36, 166, 10.1111/j.1365-2710.2010.01167.x Yan, 2007, Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome, Am Heart J, 154, 1108, 10.1016/j.ahj.2007.07.040 Hussain, 2013, Drug use evaluation of dabigatran in a tertiary care hospital in United Arab Emirates, Eur J Hosp Pharm, 20, 106, 10.1136/ejhpharm-2012-000169 Smythe, 2013, Rivaroxaban: practical considerations for ensuring safety and efficacy, Pharmacotherapy, 33, 1223, 10.1002/phar.1289 Camm, 2012, 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association, Eur Heart J, 33, 2719, 10.1093/eurheartj/ehs253 Pisters, 2010, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, 138, 1093, 10.1378/chest.10-0134 Lip, 2011, J Am Coll Cardiol, 57, 173, 10.1016/j.jacc.2010.09.024 Zaugg, 2006 van Walraven, 2006, Effect of study setting on anticoagulation control: a systematic review and metaregression, Chest, 129, 1155, 10.1378/chest.129.5.1155 Oake, 2007, Frequency of adverse events in patients with poor anticoagulation: a meta-analysis, CMAJ, 176, 1589, 10.1503/cmaj.061523 Lavoie, 2004, Preinjury warfarin use among elderly patients with closed head injuries in a trauma center, J Trauma, 56, 802, 10.1097/01.TA.0000066183.02177.AF Franko, 2006, Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma, J Trauma, 61, 107, 10.1097/01.ta.0000224220.89528.fc Cohen, 2006, Traumatic brain injury in anticoagulated patients, J Trauma, 60, 553, 10.1097/01.ta.0000196542.54344.05 Inui, 2014, Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation/flutter: a long-term analysis of risk versus benefit, J Trauma Acute Care Surg, 76, 642, 10.1097/TA.0000000000000138 Vasishta, 2001, Stroke prevention in atrial fibrillation: physicians’ attitudes to anticoagulation in older people, Arch Gerontol Geriatr, 33, 219, 10.1016/S0167-4943(01)00184-4 Fuchs, 2015, [Anticoagulation in the aged patient with atrial fibrillation: what are prescribing cardiologists, geriatricians and general practitioners?.], Rev Med Interne, 36, 509, 10.1016/j.revmed.2015.03.330 Briggs, 2009 Bates, 2012, VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines, Chest, 141, e691S, 10.1378/chest.11-2300 Kimmel, 2007, The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study, Arch Intern Med, 167, 229, 10.1001/archinte.167.3.229 Bae, 2012, Adherence and dosing frequency of common medications for cardiovascular patients, Am J Manag Care, 18, 139 Bodin, 2005, Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity, Blood, 106, 135, 10.1182/blood-2005-01-0341 Levine, 2005, Hypercoagulable states and stroke: a selective review, CNS Spectr, 10, 567, 10.1017/S109285290001021X Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Maura, 2015, Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a french nationwide propensity-matched cohort study, Circulation, 132, 1252, 10.1161/CIRCULATIONAHA.115.015710 Bénard-Laribière, 2015, Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study, Fundam Clin Pharmacol, 29, 106, 10.1111/fcp.12088 Michel, 2005, Les événements indésirables graves liés aux soins observés dans les établissements de santé: premiers résultats d’une étude nationale, Etudes et Resultats, 398, 1 Pouyanne, 2000, Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres, BMJ, 320, 1036, 10.1136/bmj.320.7241.1036 Khetta, 2015, [Which place for direct oral anticoagulants in routine hospital medical practice?.], Rev Med Interne